The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology

Top 10 Challenges in Cancer Immunotherapy

(2020) Priti S. Hegde et al.   IMMUNITY

B cells are associated with survival and immunotherapy response in sarcoma

(2020) Florent Petitprez et al.   NATURE

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

(2020) Rita Cabrita et al.   NATURE

The single-cell pathology landscape of breast cancer

(2020) Hartland W. Jackson et al.   NATURE

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma

(2020) Shogo Zuo et al.   PEDIATRIC SURGERY INTERNATIONAL

CRISPR-engineered T cells in patients with refractory cancer

(2020) Edward A. Stadtmauer et al.   SCIENCE

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies

(2020) Dana L. Casey et al.   Cancer Immunology Research

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

(2020) Celina L. Szanto et al.   Cancers

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

(2020) Ladenstein et al.   Cancers

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma

(2020) Robyn T. Sussman et al.   Frontiers in Oncology

Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies

(2020) Theodore L. Roth et al.   CELL

Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras

(2020) Malkiel A. Cohen et al.   Cell Stem Cell

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

(2020) Amod Sarnaik et al.   JOURNAL OF CLINICAL ONCOLOGY

Targets and Antibody Formats for Immunotherapy of Neuroblastoma

(2020) Jeong A. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

A conserved dendritic-cell regulatory program limits antitumour immunity

(2020) Barbara Maier et al.   NATURE

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

(2020) Michal Slyper et al.   NATURE MEDICINE

Control of brain tumor growth by reactivating myeloid cells with niacin

(2020) Susobhan Sarkar et al.   Science Translational Medicine

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

(2020) Constance J. Martin et al.   Science Translational Medicine

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

(2020) Maud Mayoux et al.   Science Translational Medicine

Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy

(2020) Joseph D. Butner et al.   Science Advances

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

(2020) Rosa Nguyen et al.   Journal for ImmunoTherapy of Cancer

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma

(2020) Karoline Ehlert et al.   Journal for ImmunoTherapy of Cancer

CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment

(2020) Chao Xin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor‐stroma drug targeting

(2020) Anna Kock et al.   FASEB JOURNAL

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

(2020) Lorenzo Galluzzi et al.   Nature Reviews Clinical Oncology

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors

(2020) Ombretta Melaiu et al.   SEMINARS IN CANCER BIOLOGY

MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy

(2020) Annelisa M. Cornel et al.   Cancers

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

(2020) Andras Heczey et al.   NATURE MEDICINE

Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation

(2019) Kazuaki Harada et al.   CANCER SCIENCE

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM1 receptors

(2019) Irene Veneziani et al.   Oncotarget

Engineering the TGFβ receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma

(2019) Rachel A Burga et al.   CLINICAL CANCER RESEARCH

Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells

(2019) Hong-Wei Wu et al.   CLINICAL CANCER RESEARCH

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

(2019) Amir A. Jazaeri et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: A Children's Oncology Group phase II study

(2019) Suzanne Shusterman et al.   CLINICAL CANCER RESEARCH

Diminished cytolytic activity of γδ T cells with reduced DNAM-1 expression in neuroblastoma patients

(2019) Xiaolin Wang et al.   CLINICAL IMMUNOLOGY

Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression

(2019) Sherly Mardiana et al.   Science Translational Medicine

Location, location, location: Tissue resident memory T cells in mice and humans

(2019) Peter A. Szabo et al.   Science Immunology

In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis.

(2019) Orli Yogev et al.   CANCER RESEARCH

Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function

(2019) Marina Ollé Hurtado et al.   PLoS One

Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies

(2019) Alessandra Marrella et al.   Frontiers in Immunology

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

CAR-NK for tumor immunotherapy: Clinical transformation and future prospects

(2019) Wenxiu Wang et al.   CANCER LETTERS

Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome

(2019) Eva Hlavackova et al.   Frontiers in Oncology

Overexpression of Macrophage Migration Inhibitory Factor and Its Homologue D-Dopachrome Tautomerase as Negative Prognostic Factor in Neuroblastoma

(2019) Cavalli et al.   Brain Sciences

Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma

(2019) M.L. Tas et al.   EUROPEAN JOURNAL OF CANCER

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

(2019) David Liu et al.   NATURE MEDICINE

Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma

(2019) Young Bae Choi et al.   PLoS One

Cellular components in tumor microenvironment of neuroblastoma and the prognostic value

(2019) Xiaodan Zhong et al.   PeerJ

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

(2019) Julie Voeller et al.   Journal for ImmunoTherapy of Cancer

Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma

(2018) Liulin Yang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Spontaneous regression of neuroblastoma

(2018) Garrett M. Brodeur   CELL AND TISSUE RESEARCH

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-riskMYCN-not-amplified Human Neuroblastoma

(2018) Jun S. Wei et al.   CLINICAL CANCER RESEARCH

The landscape of genomic alterations across childhood cancers

(2018) Susanne N. Gröbner et al.   NATURE

Myeloid-derived suppressor cells coming of age

(2018) Filippo Veglia et al.   NATURE IMMUNOLOGY

PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease

(2018) Priya Srinivasan et al.   PLOS MEDICINE

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

(2018) M. Fevzi Ozkaynak et al.   Frontiers in Immunology

Nedd4 Binding Protein 1 (N4BP1) and TNFAIP3 Interacting Protein 1 (TNIP1) control MHC-1 display in neuroblastoma

(2018) Lotte Spel et al.   CANCER RESEARCH

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

(2018) Noam Auslander et al.   NATURE MEDICINE

The hallmarks of successful anticancer immunotherapy

(2018) Lorenzo Galluzzi et al.   Science Translational Medicine

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

(2018) Xian Shen et al.   BMJ-British Medical Journal

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

(2018) Chiara Camisaschi et al.   BMC CANCER

Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells

(2018) Gloria Pelizzo et al.   BMC CANCER

Organoid Modeling of the Tumor Immune Microenvironment

(2018) James T. Neal et al.   CELL

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

(2018) Ruth Ladenstein et al.   LANCET ONCOLOGY

CAR T Cell Therapy for Neuroblastoma

(2018) Rebecca M. Richards et al.   Frontiers in Immunology

Secretory High-Mobility Group Box 1 Protein Affects Regulatory T Cell Differentiation in Neuroblastoma Microenvironment In Vitro

(2018) Thitinee Vanichapol et al.   Journal of Oncology

Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma

(2017) Naonori Kawakubo et al.   JOURNAL OF PEDIATRIC SURGERY

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

(2017) Rajen Mody et al.   LANCET ONCOLOGY

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Invariant natural killer T infiltration in neuroblastoma with favorable outcome

(2017) Tomoro Hishiki et al.   PEDIATRIC SURGERY INTERNATIONAL

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

(2017) Valentina Rigo et al.   Scientific Reports

The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors

(2017) Thanh-Phuong Le et al.   Frontiers in Immunology

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database

(2017) Peng Zhang et al.   Frontiers in Immunology

Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression

(2017) Julian P. Layer et al.   OncoImmunology

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO

(2017) Nikolai Siebert et al.   OncoImmunology

MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma

(2017) Elisa Brandetti et al.   OncoImmunology

TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells

(2016) Hung C. Tran et al.   CLINICAL CANCER RESEARCH

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

(2016) Y. Mao et al.   CLINICAL CANCER RESEARCH

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma

(2016) Christopher J. Forlenza et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion

(2016) Zijun Zhen et al.   Oncotarget

Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients

(2016) Fabio Morandi et al.   Journal of Immunology Research

Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma

(2016) Gabriele Büchel et al.   OncoImmunology

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival

(2016) Nikolai Siebert et al.   OncoImmunology

Neuroblastoma

(2016) Katherine K. Matthay et al.   Nature Reviews Disease Primers

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

(2015) Deepa K. Krishnadas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells

(2015) Marianne Boes et al.   CANCER LETTERS

Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity

(2015) F. Mussai et al.   CANCER RESEARCH

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

(2015) Navin R. Pinto et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies

(2015) Walter Cacciavillano et al.   PEDIATRIC BLOOD & CANCER

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

(2015) Michaela Semeraro et al.   Science Translational Medicine

Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma

(2015) Lotte Spel et al.   Oncotarget

Expression ofFOXP3,CD14, andARG1in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival

(2015) Sara Stigliani et al.   Biomed Research International

IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome

(2015) Fabio Morandi et al.   Journal of Immunology Research

Natural killer cell mediated immunosurveillance of pediatric neuroblastoma

(2015) Michaela Semeraro et al.   OncoImmunology

Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma

(2015) Marco Mina et al.   OncoImmunology

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance

(2015) Alessandra Dondero et al.   OncoImmunology

PD-L1 and CD8+PD1+lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy

(2015) Ferdousi Chowdhury et al.   OncoImmunology

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

(2014) Brian H. Kushner et al.   CLINICAL CANCER RESEARCH

Expression of Macrophage Migration Inhibitory Factor by Neuroblastoma Leads to the Inhibition of Antitumor T Cell Reactivity In Vivo

(2014) Q. Zhou et al.   JOURNAL OF IMMUNOLOGY

Immunoglobulin GM and FcγRIIIa genotypes influence cytotoxicity of neuroblastoma cells

(2014) Janardan P. Pandey et al.   JOURNAL OF NEUROIMMUNOLOGY

Circulating T-Regulatory Cells in Neuroblastoma: A Pilot Prospective Study

(2014) TVSVGK Tilak et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment

(2014) G Bianchi et al.   Cell Death & Disease

Natural Killer Cells and Neuroblastoma: Tumor Recognition, Escape Mechanisms, and Possible Novel Immunotherapeutic Approaches

(2014) Cristina Bottino et al.   Frontiers in Immunology

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival

(2013) Richard K. Yang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma

(2013) Lena-Maria Carlson et al.   CARCINOGENESIS

Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells

(2013) G. Santilli et al.   CLINICAL CANCER RESEARCH

Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

(2013) E. L. Williams et al.   CLINICAL CANCER RESEARCH

The immune environment of paediatric solid malignancies: evidence from an immunohistochemical study of clinical cases

(2013) John R. Apps et al.   Fetal and Pediatric Pathology

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

(2013) Gabriela Bindea et al.   IMMUNITY

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma

(2013) Michiel Kroesen et al.   INTERNATIONAL JOURNAL OF CANCER

The genetic landscape of high-risk neuroblastoma

(2013) Trevor J Pugh et al.   NATURE GENETICS

The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes

(2013) Lena-Maria Carlson et al.   OncoImmunology

Neuroblastoma-related inflammation

(2013) Lena-Maria Carlson et al.   OncoImmunology

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

(2012) Nidale Tarek et al.   JOURNAL OF CLINICAL INVESTIGATION

Examining T Cells at Vaccine Sites of Tumor-bearing Hosts Provides Insights to Dysfunctional T-Cell Immunity

(2012) Kristen M. Barr et al.   JOURNAL OF IMMUNOTHERAPY

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

(2011) Thorsten Simon et al.   BMC CANCER

Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments

(2011) Rocio Soldati et al.   INTERNATIONAL JOURNAL OF CANCER

NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT

(2011) Justyna Kanold et al.   PEDIATRIC BLOOD & CANCER

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc  Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

(2010) D. C. Delgado et al.   CANCER RESEARCH

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon- -Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo

(2009) G. S.D. Reid et al.   CLINICAL CANCER RESEARCH

Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

(2009) Liping Song et al.   JOURNAL OF CLINICAL INVESTIGATION

Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells

(2008) Lena-Maria Carlson et al.   CELL RESEARCH

Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule

(2008) A Gregorio et al.   HISTOPATHOLOGY

A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma

(2008) Heidi V. Russell et al.   JOURNAL OF IMMUNOTHERAPY

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE